Sarepta says it won’t comply with FDA request to stop shipping gene therapy Elevidys Reuters Sarepta Refuses FDA Request to Stop Shipping Muscular Dystrophy Drug Elevidys The New York Times Sarepta shares plunge 40% as future of its gene therapy appears at risk CNBC Third death from a Sarepta gene therapy biocentury.com We are mothers of Duchenne patients. Recent setbacks with Sarepta must not …
Read More »Tag Archives: ELEVIDYS
Exclusive: US FDA to ask Sarepta to stop shipments of gene therapy Elevidys, source says – Reuters
Exclusive: US FDA to ask Sarepta to stop shipments of gene therapy Elevidys, source says Reuters Sarepta shares plunge 40% as future of its gene therapy appears at risk CNBC FDA to Ask Sarepta to Stop Shipping Muscular Dystrophy Drug Elevidys The New York Times Third death from a Sarepta gene therapy BioCentury FDA Is Investigating If Sarepta’s Gene Therapy Should Stay on Market Bloomberg …
Read More »Sarepta stock falls on FDA gene therapy Elevidys comment
Douglas Ingram, president and chief executive officer of Sarepta Therapeutics Inc., during the Forbes Healthcare Summit in New York, US, on Tuesday, Dec. 5, 2023. Michael Nagle | Bloomberg | Getty Images Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy treatment appeared at risk. The Food and Drug Administration will …
Read More »Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label – Sarepta Therapeutics
Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label Sarepta TherapeuticsView Full Coverage on Google News Source link
Read More »